The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
While GLP-1 medications are celebrated for their effectiveness in managing type 2 diabetes and aiding weight loss, a growing concern is the potential for nutrient deficiencies. This article delves into the science behind this 'under-the-radar' side effect and what proactive steps you can take.
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
A major bust at a country estate near Northampton has led to the seizure of 12,000 doses of illicit weight loss medications, including potent peptide drugs. Two men have been arrested as the Medicines and Healthcare products Regulatory Agency (MHRA) cracks down on dangerous counterfeit and unlicensed medicines.
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
The rapid adoption of GLP-1 agonists like Ozempic and Wegovy is forcing a profound realignment in the food and beverage industry. Initial hopes that users would eventually return to old habits have faded, replaced by a strategic pivot toward 'companion nutrition' tailored to the specific, evolving needs of individuals managing weight and metabolic health.
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
